Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Molecular Targeted Cancer Therapies Market Forecast
Interactive Model
Published: August 2009
Pages: For full details, please email keithw@cmsinfo.com
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 9500.00 Buy Now!
Research from: Datamonitor
Sector: Prescriptipn Medicines
Introduction
Molecular targeted cancer therapies are the biggest and fastest growing class of cancer drugs in terms of sales. As growth of revenues from cytotoxic therapies and antihormonal therapies has slowed and many key brands in these classes face imminent patent expiries, it is unsurprising that the major oncology companies have shifted their focus towards the molecular targeted cancer therapies market.
Reasons to Purchase
*Quantify the performance of each of the marketed molecular targeted cancer therapies in the seven major markets over the period 2008 to 2018
*Assess the changing key opportunities and threats both for currently marketed and pipeline targeted therapy cancer brands
*Identify the leading brands in this market over the next 10 years and understand the key factors driving their success
Molecular targeted cancer therapies are the biggest and fastest growing class of cancer drugs in terms of sales. As growth of revenues from cytotoxic therapies and antihormonal therapies has slowed and many key brands in these classes face imminent patent expiries, it is unsurprising that the major oncology companies have shifted their focus towards the molecular targeted cancer therapies market.
Reasons to Purchase
*Quantify the performance of each of the marketed molecular targeted cancer therapies in the seven major markets over the period 2008 to 2018
*Assess the changing key opportunities and threats both for currently marketed and pipeline targeted therapy cancer brands
*Identify the leading brands in this market over the next 10 years and understand the key factors driving their success